Acrivon Therapeutics, Inc. Debt Securities, Available-for-sale, Current
Acrivon Therapeutics, Inc. (ACRV) had Debt Securities, Available-for-sale, Current of $85.37 million as of 2024-03-31, per its 10-Q filed 2024-05-14.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2024-11-13
- 2024-03-31: Debt Securities, Available-for-sale, Current $85.37M.
- 2023-12-31: Debt Securities, Available-for-sale, Current $91.44M.
- 2022-09-30: Debt Securities, Available-for-sale, Current $44.74M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2024-03-31 | $85.37M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $91.44M 10-Q · filed 2024-11-13 |
| 2022-09-30 | $44.74M 10-Q · filed 2022-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |